MedDataX Logo

To Demonstrate the Relative Bioequivalency of Cord's 100 mg Desipramine HCL Tablets To Merrell Dow's 100 mg Norpramin Tablets

NCT ID: NCT00913809

Last Updated: 2017-03-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

1987-12-31

Study Completion Date

1987-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To demonstrate the relative bioequivalency of Cord's 100 mg Desipramine HCl tablets to Merrell Dow's 100 mg Norpramin tablets.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride Tablets

NCT00913822

Depression
COMPLETED PHASE1

A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication

NCT04937829

Depressive Disorder, Major
COMPLETED PHASE1

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

NCT01111539

Major Depressive Disorder (MDD)
TERMINATED PHASE3

Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major Depression

NCT00320632

Depression
COMPLETED PHASE4

Patient Tolerability Study of GSK163090

NCT00559299

Depressive Disorder, Major Major Depressive Disorder (MDD)
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Desipramine HCL 100 mg Tablets Cord Laboratories

Group Type EXPERIMENTAL

Desipramine HCL 100 mg Tablets Cord Laboratories

Intervention Type DRUG

2

Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc

Group Type ACTIVE_COMPARATOR

Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Desipramine HCL 100 mg Tablets Cord Laboratories

Intervention Type DRUG

Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria

* Positive test results for HIV or hepatitis B or C.
* Treatment for drug or alcohol dependence.
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sandoz

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sandoz Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jules Kann, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Biodecision Laboratories

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

870609-D

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder
NCT01413932 COMPLETED PHASE1/PHASE2
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
NCT01098240 TERMINATED PHASE2
Biological Aspects of Depression and Antidepressant Drugs
NCT00018733 COMPLETED NA
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
NCT06564818 RECRUITING PHASE3
Treatment Choices for Improving Adherence and Outcome
NCT00194948 COMPLETED NA
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01123707 TERMINATED PHASE3
An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression
NCT00070694 COMPLETED PHASE2
A Study to Test Different Doses of BI 1569912 in People With Depression
NCT06558344 COMPLETED PHASE2
Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder
NCT05952713 COMPLETED
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01111565 TERMINATED PHASE3
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01111552 TERMINATED PHASE3
Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)
NCT00610649 COMPLETED PHASE2
Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
NCT03606395 COMPLETED PHASE1
An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder
NCT00415142 COMPLETED PHASE3
Treatment Response of Geriatric Depression
NCT00754936 COMPLETED NA
Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder
NCT00109044 COMPLETED PHASE3
Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers
NCT00536679 COMPLETED PHASE1
A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression
NCT00566202 COMPLETED PHASE2
Identifying Factors That Predict Antidepressant Treatment Response
NCT00360399 COMPLETED NA
A Study of HS-10353 in Adult Participants With Major Depressive Disorder
NCT05938179 UNKNOWN PHASE2
A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder
NCT02724735 UNKNOWN
Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression
NCT05018013 UNKNOWN PHASE2
The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD
NCT00163059 COMPLETED PHASE2
Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder
NCT01380704 COMPLETED PHASE1
A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.
NCT00775203 COMPLETED PHASE3